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Role of hyperlipidemia in progressive renal disease: Focus on of LDL, and increases in apoprotein (a) [1]. It has been
diabetic nephropathy. suggested that hyperlipidemia is an important aggravat-
Background. It has been suggested that lipids promote renal ing factor in the progression of kidney disease. This studyinjury and that 3-hydroxy-3-methylglutaryl coenzyme A (HMG
explores the role of lipid-lowering treatment in theCoA) reductase inhibitors confer renoprotection in certain re-
subtotal nephrectomy (STNx) model, which has manynal diseases, including diabetic nephropathy.
Methods. Sprague-Dawley rats were randomized to sham, similarities to experimental diabetes, including hyperfil-
subtotal nephrectomy (STNx) or STNx 1 atorvastatin groups. tration, progressive glomerulosclerosis, and tubuloin-
After 12 weeks, proteinuria, renal function, glomerular injury,
terstitial injury, as well as changes in growth factor ex-renal transforming growth factor-b (TGF-b) gene expression
pression, including increased renal transforming growthand macrophage (ED1-positive cells) accumulation were as-
sessed. In addition, the effects of HMG CoA reductase in human factor-b1 (TGF-b1) [2]. Furthermore, the possibility that
diabetic nephropathy were reviewed. these beneficial effects of lipid-lowering treatment,
Results. Atorvastatin therapy was associated with a modest which have been reported in rodent models of progres-
reduction in proteinuria and glomerulosclerosis without influ-
sive renal injury, are also observed in humans is evalu-encing lipid levels or renal function in STNx rats. These effects
ated by reviewing recent clinical data on 3-hydroxy-3-were associated with decreased renal TGF-b1 gene expression
and less glomerular and tubulointerstitial macrophage accumu- methylglutaryl coenzyme A (HMG CoA) reductase
lation. The renoprotective effects of HMG CoA reductase in- inhibitors in diabetic patients with early and overt DN.
hibitors in both insulin- and non–insulin-dependent diabetic
subjects with either incipient or overt nephropathy appear to
be highly variable. METHODS
Conclusions. HMG CoA reductase inhibition appears to
Male Sprague-Dawley rats weighing 200 to 250 g un-confer renoprotection via effects on prosclerotic cytokines such
as TGF-b and macrophage accumulation, independent of their derwent 5/6th STNx. As previously described [2], a STNx
lipid-lowering properties. The role of lipid-lowering agents in was performed by right subcapsular nephrectomy and
early or overt diabetic nephropathy remains to be fully ascer- infarction of approximately two thirds of the left kidneytained.
by selective ligation of two to three extrarenal branches
of the left renal artery. Eight rats underwent sham opera-
tion. Following the operation, the rats with STNx wereDiabetic nephropathy (DN) remains the major cause
randomly assigned to receive either atorvastatin (20 mg/of end-stage renal failure in the Western world. This
kg body wt, N 5 13) by daily gavage or placebo (N 5 8)condition is characterized by hypertension, proteinuria,
for 12 weeks. After 12 weeks, systolic blood pressureand declining renal function. Before the onset of DN,
was measured by a plethysmographic tail cuff method.there is a phase known as microalbuminuria that is asso-
Animals were weighed, and 24-hour urine was collectedciated with a modest increase in blood pressure and
for the determination of protein excretion. Animals weresubtle changes in lipoproteins. These include minor in-
sacrificed and plasma was collected for urea, creatinine,creases in low-density lipoprotein (LDL) cholesterol, in-
cholesterol, and triglycerides, which were subsequentlycreases in apolipoprotein B, an increase of the density
measured by an autoanalyzer. The kidneys were removed,
weighed, and further processed for in situ hybridization
and immunohistochemistry (discussed later in this arti-Key words: diabetes, HMG CoA reductase inhibition, renoprotection,
lipid lowering agents, renal injury, atorvastatin therapy. cle). Glomerular filtration rate (GFR) was measured
by a single-shot isotopic method using 99mTc-DTPA [2]. 1999 by the International Society of Nephrology
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Table 1. Functional and structural parameters
Sham STNx STNx1atorvastatin
N 8 8 13
SBP mm Hg 12665 17566a 17766a
Body weight g 547623 451623a 404617a
Kidney weight g 1.560.1 1.960.2a 1.960.1a
Urea mmol/liter 6.960.1 17.062.0a 15.860.8a
Creatinine mmol/liter 5462 106618a 8764a
Cholesterol mmol/liter 2.460.1 3.960.4a 3.760.2a
Triglycerides mmol/liter 1.0160.07 1.1360.12 0.92 60.06
GFR ml/min 3.4560.32 0.7060.16a 0.7360.10a
Proteinuria mg/24 hr 2162 389689a 224632a,b
Glomerulosclerotic index 0.3860.08 2.7660.11a 2.3760.15a,b
TGF-b1 dpm/mm2 8365 183618a 144613a,b
Glomerular ED-1 staining
positive cells/glomeruli 0.10 (0.01–0.50) 0.55 (0.1–1.5)a 0.13 (0–0.48)b
Tubulointerstitial ED-1 staining
positive cells/field 1.4 (0.7–4.2) 8.0 (3.4–44.3)a 2.9 (2.0–9.0)c
Data are shown as mean 6 sem except for ED-1 staining data, which are shown as median (interquartile range). Abbreviations are: STNx, subtotal nephrectomy;
N, number; SBP, systolic blood pressure; Body wt, body weight; GFR, glomerular filtration rate; TGF-b1, transforming growth factor-b1.
aP , 0.01 vs. sham
bP , 0.05.
cP 5 0.07 vs. STNx
Glomerular injury was assessed by examining 70 glome- placebo-treated rats (Table 1). Systolic blood pressure
ruli in periodic acid-Schiff–stained sections. Each glome- was significantly elevated in both 5/6th nephrectomized
rulus was graded in terms of severity, and a glomerulo- groups compared with the sham group, but atorvastatin
sclerotic index was calculated as previously described [3]. did not influence blood pressure (Table 1). Remnant
The presence of mononuclear leukocytes was demon- kidney weights were significantly higher in both STNx
strated immunohistochemically using the indirect avidin- groups, but this parameter was not influenced by atorvas-
biotinylated peroxidase method. Sections were incubated tatin treatment. All STNx rats had evidence of renal
with a murine monoclonal primary IgG antibody specific impairment, with elevated plasma urea and creatinine
for the monocyte/macrophage antigen, ED-1 (Serotec, concentrations, as well as reduced GFR. No parameter
Oxford, UK). The immunostaining was quantitated by of renal function was affected by atorvastatin treatment.
counting the number of positive cells in 20 glomeruli
Total cholesterol was elevated in STNx rats. Atorvastatin
and 20 grid fields (0.1 mm2) [4]. In situ hybridization
did not affect any lipid parameter. STNx rats had in-for TGF-b1 was performed on 4 mm thick sections of
creased proteinuria, and this parameter was significantlyformalin-fixed, paraffin-embedded tissues as previously
reduced by atorvastatin after 12 weeks of treatment.described [2]. Gene expression for TGF-b1 was analyzed
STNx was associated with the development of glomeru-on autoradiographs from each animal using a Micro
losclerosis, which was attenuated but not prevented byComputer Imaging Device (Imaging Research, Ontario,
atorvastatin (Table 1). STNx was associated with in-Canada).
creased renal TGF-b1 gene expression, which was atten-
Statistics uated but not normalized by atorvastatin therapy (Fig.
1 and Table 1). ED-1 staining in both glomeruli and theData are shown as mean 6 sem except for data not
normally distributed where medians and interquartile tubulointerstitium was increased in STNx rats (Fig. 2).
ranges are shown. Analyses were performed by analysis Atorvastatin reduced ED-1 staining in glomeruli with a
of variance in the case of normally distributed data or similar trend in the tubulointerstitium, which did not
using the Kruskal–Wallis test if data were not normally reach statistical significance (Fig. 2 and Table 1).
distributed. A P value less than 0.05 was viewed as statis-
tically significant. DISCUSSION
This study has confirmed Kasiske et al’s previous study
RESULTS showing that lipid-lowering treatment in the STNx model
is associated with attenuated development of proteinuriaAfter 12 weeks, the body weights of the STNx animals
[5]. In this study, no effect on lipid parameters was ob-were significantly reduced compared with the sham-
served in these rodents treated with atorvastatin. There-operated animals, but there was no significant difference
between the body weights of the atorvastatin and fore, the renoprotective effects observed in this study
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Table 2. Effect of HMG CoA reductase inhibitors on albuminuria in diabetic subjects with early and overt renal disease
Type of
Agent Type of study Duration N diabetes Stage of renal disease Proteinuria Reference
Simvastatin/placebo Placebo 12 weeks 14 1 Proteinuria → Hommel et al
Controlled 12 (1992) [19]
Simvastatin/placebo Placebo 18–30 months 11 1 Microalbuminuria → Barnes et al
Controlled 12 (1998) [27)
Pravastatin/placebo Cross-over 12 weeks active/ 20 1 Microalbuminuria → Zhang et al
12 weeks placebo (1995) [20]
Lovastatin Uncontrolled 12 weeks 10 1 Proteinuria → Biesenbach et al
(1992) [21]
Simvastatin/placebo Placebo 36 weeks 8 2 Microalbuminuria → Nielsen et al
Controlled 10 (1993) [22]
Pravastatin Uncontrolled 12 weeks 9 2 Proteinuria ↓ Sasaki et al
(1990) [17]
Pravastatin Uncontrolled 12 weeks 12 2 Predominantly ↓ (.50%) Shoji et al
proteinuric (1991) [18]
Lovastatin/placebo Placebo 2 years 16 2 Proteinuria ↑ Lam et al
Controlled 18 ↑ (1995) [23]
(↓ GFR in
placebo group)
Simvastatin/placebo Cross-over 1 year active/ 19 2 Microalbuminuria/ ↓ (225%) Tonolo et al
1 year placebo Normal BP (1997) [26]
appear to be independent of the drug’s hypolipidemic protein-induced renal damage [9]. Although speculative,
it is possible that the concomitant effect of atorvastatinaction. The beneficial effect on proteinuria was associ-
ated with reduced renal TGF-b1 expression and less on proteinuria and macrophage accumulation may be
linked to the capacity of these agents to inhibit MCP-1macrophage infiltration in both glomeruli and the tubu-
lointerstitium. gene expression.
Although lipid-lowering agents have been shown in aMultiple mechanisms for these effects of HMG CoA
reductase inhibitors have been described, including those range of experimental models to confer variable degrees
of renoprotection, their role in both experimental andcaused by reduction in nonsterol products such as iso-
prenoids, which are intimately involved in DNA replica- clinical diabetes remains uncertain. Indeed, the role of
lipids per se in aggravating experimental DN remainstion [6]. HMG CoA reductase inhibition was associated
with reduced macrophage accumulation in this study, as controversial. There are reports of cholesterol feeding
attenuating, aggravating, or having no effect on experi-has been reported in other models of renal disease [7].
Macrophages are a major source of proliferative and mental DN [10–12]. Nevertheless, the potential renopro-
tective role of HMG CoA reductase inhibitors in humanprosclerotic cytokines [8]. Our own group has docu-
mented localization of TGF-b1 within macrophages in DN has been investigated over the last decade in a range
of studies that have, in general, been of relatively shortthe model of STNx and has shown that reduction in
TGF-b1 gene expression with inhibition of the renin- duration and only in a limited number of subjects
(Table 2).angiotensin system is associated with reduced macro-
phage infiltration and local proliferation [8]. Furthermore, These lipid-lowering agents are already widely used
in diabetes, as this is a state of accelerated atherosclerosisthe chemokine, monocyte chemoattractant protein-1
(MCP-1), has been suggested to play a pivotal role in with increased prevalence of a range of lipid abnormali-
ties [13]. Furthermore, lipid-lowering therapy has beenmediating lipid-induced nephrotoxicity, and lovastatin
reduces gene expression of this protein [7]. shown to be particularly useful in reducing cardiovascu-
lar morbidity and mortality in diabetic subjects with mod-Although atorvastatin retarded the development of
proteinuria, there was no effect on renal function. This erate hypercholesterolemia and established vascular dis-
ease [13]. Hypercholesterolemia has been shown in awould imply that in the STNx model, the major determi-
nants of progressive decline in GFR are other factors number of epidemiological studies to be linked to the
progression of nephropathy. For example, in an analysissuch as systemic hypertension and the status of the local
renin-angiotensin system. Atorvastatin did not affect of 439 type 1 diabetic patients with nephropathy who
participated in the Diabetic Retinopathy Study, a rapidblood pressure and is unlikely to influence the intrarenal
renin-angiotensin system directly. decline in renal function was associated not only with
elevated blood pressure, but also with increased plasmaThe importance of MCP-1 is further suggested from
studies by Remuzzi, Ruggenenti, and Benigni, which em- cholesterol levels [14]. Similar links between plasma cho-
lesterol levels and a decline in renal function have alsophasize the role of this protein in mediating tubular
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Fig. 1. Autoradiographs are shown for renal
transforming growth factor-b1 (TGF-b1)
gene expression in sham (A), subtotal ne-
phrectomy (STNx) (B) and STNx 1 atorvas-
tatin groups (C). Publication of this figure in
color was made possible by a grant from
Parke-Davis and Pfizer.
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been reported in post hoc analyses of several studies
exploring the role of angiotensin-converting enzyme in-
hibition in type I and type II diabetic patients with early
or overt renal disease [15, 16]. However, these studies
only describe association, and therefore, intervention
studies with lipid-lowering agents are required to test
directly the hypothesis that lipid-lowering agents confer
renoprotection in the diabetic population.
HMG CoA reductase inhibitors have been shown to
be effective lipid-lowering agents in both type I and
type II diabetic patients, with no evidence that diabetic
patients are resistant to the LDL-lowering effects of
these agents [13]. However, their role as renoprotective
agents remains controversial. Most studies suggest no or
only a minimal effect on proteinuria over weeks to
months (Table 2). Furthermore, the effects on renal func-
tion have not been generally performed or have used
insensitive markers such a serum creatinine.
The initial studies were uncontrolled and involved pre-
treatment and posttreatment assessment of the HMG
CoA reductase inhibitor pravastatin for 12 weeks [17,
18]. These pilot studies were suggestive of an effect of
pravastatin on albuminuria. This was followed by a series
of placebo-controlled and cross-over studies with a range
of HMG CoA reductase inhibitors, most of these studies
showing minimal evidence of a reduction in albuminuria
with these agents in type I [19–21] or type II diabetic
subjects [22]. In a placebo-controlled study performed
in Hong Kong over two years, it was suggested that
despite no significant effect on proteinuria, a decline in
renal function was attenuated by lovastatin, particularly
over the second year of the study [23]. However, these
findings have been disputed by several investigators who
suggested that the statistical analysis used was inappro-
priate [24, 25]. Tonolo et al reported in a cross-over
study, which included a 12-month active treatment pe-
riod with simvastatin, an approximate 25% decrease in
proteinuria in a group of normotensive, microalbumi-
nuric type II diabetic patients [26]. However, these find-
ings must be interpreted with caution in view of the lack
of confirmation of similar findings by other groups [27].
Despite generally positive findings for lipid-lower-
ing agents in experimental models of renal disease, these
agents cannot be considered first-line renoprotective
agents. Even if these agents are potentially beneficial in
human DN, it appears likely that HMG CoA reductase
Fig. 2. ED-1 staining is shown in glomeruli and the tubulointerstitium
in sham (A), STNx (B), and STNx 1 atorvastatin groups (C) (magnifi-
cation 3400). Publication of this figure in color was made possible by
a grant from Parke-Davis and Pfizer.
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